Contineum MS drug stumbles in mid-stage trial
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Desai is currently serving the company as Group Finance Controller
Winlevi is authorized in EU for the treatment of acne vulgaris
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Subscribe To Our Newsletter & Stay Updated